Contineum Therapeutics (CTNM) Non-Current Assets: 2023-2025
Historic Non-Current Assets for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $5.9 million.
- Contineum Therapeutics' Non-Current Assets rose 564.42% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 564.42%. This contributed to the annual value of $6.5 million for FY2024, which is 141.01% up from last year.
- Latest data reveals that Contineum Therapeutics reported Non-Current Assets of $5.9 million as of Q3 2025, which was down 2.13% from $6.0 million recorded in Q2 2025.
- Over the past 5 years, Contineum Therapeutics' Non-Current Assets peaked at $6.5 million during Q4 2024, and registered a low of $891,000 during Q3 2024.
- Moreover, its 3-year median value for Non-Current Assets was $4.9 million (2024), whereas its average is $4.1 million.
- Data for Contineum Therapeutics' Non-Current Assets shows a peak YoY spiked of 564.42% (in 2025) over the last 5 years.
- Over the past 3 years, Contineum Therapeutics' Non-Current Assets (Quarterly) stood at $2.7 million in 2023, then soared by 141.01% to $6.5 million in 2024, then surged by 564.42% to $5.9 million in 2025.
- Its Non-Current Assets stands at $5.9 million for Q3 2025, versus $6.0 million for Q2 2025 and $6.1 million for Q1 2025.